Intravenous administration of allogeneic Wharton jelly–derived mesenchymal stem cells for treatment of dogs with congestive heart failure secondary to myxomatous mitral valve disease

Abstract

This study showed that MSCs can be easily collected from canine Wharton jelly as an allogeneic source of MSCs and can be safely delivered IV to dogs with CHF secondary to MMVD.